EIF2A and hepatocellular carcinoma: Second, formation of SGs in HCC treated with sorafenib correlates with phosphorylation of eIF2α, which was significantly higher in SGs-forming Hep3B than in SGs-deficient Huh-7 (Figs. 2 and S2).